Centrally Acting Agents
Centrally Acting Agents - Related Videos
01:24
Centrally Acting Muscle Relaxants: Therapeutic Uses
0 Views •
2023
Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system. Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
01:30
Adrenergic Agonists: Direct-Acting Agents
0 Views •
2023
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine. These agents can be classified...
01:25
Adrenergic Agonists: Indirect-Acting Agents
0 Views •
2023
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors. One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
01:09
Peripherally and Centrally Acting Muscle Relaxants: A Comparison
0 Views •
2023
Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses. Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic drugs,...
02:11
Forces Acting on Chromosomes
0 Views •
2021
During mitosis, chromosome movements occur through the interplay of multiple piconewton level forces. In prometaphase, these forces help in chromosome assembly or congression at the equatorial plane, eventually leading to their alignment at the metaphase plate. The forces acting on the chromosomes are space and time-dependent; therefore, they vary with the position of the chromosomes as the cell progresses through mitosis. Microtubules and motor proteins exert two types of forces on...
FAQs
Crossing the blood-brain barrier allows these drugs to reach neurons in the brain or spinal cord, where they can modify receptor activity, neurotransmitter release, or neuronal excitability. The extent and selectivity of central exposure influence both therapeutic effects and behavioral changes. Pharmacokinetic evaluation therefore helps relate drug distribution and persistence to the intended neural response.
Agonists activate specific receptors, whereas antagonists block receptor activation or reduce signaling through that pathway. Reuptake mechanisms alter neurotransmitter availability by affecting its removal from the space between neurons. These distinct actions can produce different changes in neural circuits, helping explain why agents within the same broad therapeutic area may have different benefits, adverse effects, or interaction profiles.
Receptor selectivity helps researchers determine which neural pathways a drug influences and may clarify why particular therapeutic effects occur. Changes in neuronal excitability, the tendency of neurons to generate signals, can alter circuit activity throughout the central nervous system. Examining both properties supports interpretation of desired responses alongside unwanted behavioral or neurological effects.
Their effects vary with the neural processes and circuits they modify. Analgesics target pain-related responses, while sedatives and anesthetics alter central activity associated with reduced responsiveness. Antidepressants and antipsychotics influence different aspects of behavior and mood, and other agents address neurological disorders. Comparing these classes requires attention to mechanism, receptor selectivity, pharmacokinetics, and adverse-effect patterns.
Researchers examine how the drug is absorbed, distributed, and maintained in the body, with particular attention to access to the brain or spinal cord. They also characterize receptor selectivity, neurotransmitter effects, and changes in neural circuits. Together, these data connect exposure with therapeutic outcomes and help identify mechanisms that may contribute to adverse effects or drug interactions.
They are studied across several therapeutic areas, including pain management, sedation, anesthesia, depression, psychosis, and neurological disorders. Research may focus on how a candidate modifies neurotransmitter release, receptor activation, or neuronal excitability in order to produce a desired effect. These applications make the agents useful for linking molecular drug actions with broader behavioral or therapeutic outcomes.
Pharmacokinetics describes the movement and persistence of a drug in the body, including its availability to central nervous system tissues. When exposure changes, the intensity or duration of neural effects may also change. Combining pharmacokinetic findings with receptor and circuit information helps researchers interpret adverse effects, recognize possible interactions, and assess whether dosing produces a suitable therapeutic balance.
Neural-circuit analysis helps distinguish pathways associated with therapeutic benefits from those linked to unwanted behavioral or neurological effects. Researchers can then compare receptor selectivity and signaling mechanisms to identify more focused drug actions. This approach supports the development of treatments that preserve useful central nervous system effects while reducing adverse outcomes and improving the overall safety profile.